Objectives: To evaluate clinical utility of perfusion and myocardial fatty acid metabolism mismatch in SSc patients without cardiac failure. Methods: All patients who visited St. Marianna University Hospital from 2009 to 2015 and performed cardiac scintigraphy using 99m Tl and 123 I-BMIPP were retrospectively evaluated. Patients who fulfilled American Collage of Rheumatology classification criteria of SSc and systemic lupus erythematosus (SLE) were selected. We subtracted %uptake of metabolism ( 123 I-BMIPP) from that of perfusion ( 99m Tl) on each 17 myocardial segments standardized by American Heart Association. We compared sum of all the scores and each score in 3 coronary artery regions between patients with SSc and SLE. Furthermore, we evaluated incidence of cardiac death or cardiac failure depending on the scores of each coronary artery regions. Results: Among 177 patients, we analyzed the data in 22 cases with SSc and 23 with SLE. The sum of all mismatch scores was not significantly different between the 2 groups (p=0.37). The mismatch score of left anterior descending coronary artery (LAD) region was significantly higher in SSc than SLE (p=0.05) ( Figure  1A ). We next divided SSc patients into 2 groups depending on degree of the LAD mismatch score and found the group with low score had higher incidence of cardiac death or cardiac failure (p=0.04) than that with high score ( Figure 1B ). Background: Idiopathic inflammatory myopathies, also known as myositis, are a heterogeneous group of acquired diseases of probable autoimmune origin, characterized by the presence of inflammatory muscle infiltrates.Infectious complications are not uncommon in myositis, and some predisposing factors, such as upper esophageal involvement, calcinosis cutis, ventilatory insufficiency due to diaphragm involvement, and immunosuppressive drug therapies, seem to be implicated. Objectives: To describe the prevalence, clinical characteristics, and risk factors for opportunistic infection (OI) in a cohort of patients with inflammatory myopathies, and compare mortality rates between those with and without OIs. Methods: In total, 204 patients from our myositis cohort were reviewed to identify patients who had experienced an OI during the period 1986-2014. The patients' clinical characteristics, treatment received, and outcome were systematically recorded. Disease activity at the OI diagnosis and cumulative doses of immunosuppressive drugs were analyzed, as well as the specific pathogens involved and affected organs.
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A RETROSPECTIVE COHORT STUDY
A. Redondo Background: Idiopathic inflammatory myopathies, also known as myositis, are a heterogeneous group of acquired diseases of probable autoimmune origin, characterized by the presence of inflammatory muscle infiltrates.Infectious complications are not uncommon in myositis, and some predisposing factors, such as upper esophageal involvement, calcinosis cutis, ventilatory insufficiency due to diaphragm involvement, and immunosuppressive drug therapies, seem to be implicated. Objectives: To describe the prevalence, clinical characteristics, and risk factors for opportunistic infection (OI) in a cohort of patients with inflammatory myopathies, and compare mortality rates between those with and without OIs. Methods: In total, 204 patients from our myositis cohort were reviewed to identify patients who had experienced an OI during the period 1986-2014. The patients' clinical characteristics, treatment received, and outcome were systematically recorded. Disease activity at the OI diagnosis and cumulative doses of immunosuppressive drugs were analyzed, as well as the specific pathogens involved and affected organs.
Results:
The prevalence of OI in the total cohort, was 6.4%: viruses, 44.4% (varicella-zoster virus, cytomegalovirus); bacteria, 22.2% (Salmonella sp., Mycobacterium tuberculosis, M. chelonae); fungi, 16.7% (Candida albicans, Pneumocystis jirovecii); and parasites, 16.7% (Toxoplamosis gondii, Leishmania spp.) were the pathogens detected. Lung and skin/soft tissues were the organs most commonly affected (27.8%). Overall, 55.6% of OIs developed during the first year after the myositis diagnosis and were significantly associated with administration of high-dose glucocorticoids (p=0.0148). Fever at onset of myositis (p=0.0317), biological therapy (p<0.001) and sequential administration of 4 or more immunosuppressive agents during myositis evolution (p=0.0032) were significantly associated with OI. All-cause mortality in the OI group was 3.69 deaths per 100 patients/year versus 3.40 in the remainder of the cohort (p=0.996).
Conclusions:
The prevalence of OI was 6.4% in our myositis cohort. High-dose glucocorticoids at disease onset and severe immunosuppression are implicated in the development of these complications. Mortality did not differ from the remainder of the cohort. Background: Myositis-specific autoantibodies (MSA) are increasingly recognized as important diagnostic and prognostic markers in idiopathic inflammatory myopathies (IIM) (polymyositis, dermatomyositis, sporadic inclusion body myositis and necrotizing autoimmune myositis). The prevalence of these MSAs in other systemic autoimmune rheumatic diseases and neuromuscular diseases is unclear. Objectives: To compare positivity of MSA in a cohort of IIM patients to positivity in healthy controls and different systemic autoimmune rheumatic diseases (SARD) or chronic inflammatory demyelinating polyneuropathy (CIDP). Methods: A line immunoassay (Myositis 12 IgG DOT for BlueDiver) for IgG autoantibodies against Jo-1, PL-7, PL-12, EJ, SRP, Mi-2, MDA-5, TIF1-γ, HMGCR, SSA/Ro52kD, SAE1/2 and NXP-2 antigens was performed in patients with IIM (n=146), healthy controls (blood donors, n=40) and disease controls (n=200). The disease control group consisted of patients with other SARD (rheumatoid arthritis, RA; systemic sclerosis, Ssc; Sjögren's syndrome, SjS; and systemic lupus erythematosus, SLE) (n=40 for each disease group) and CIDP (n=40). A result >10 arbitrary units was considered significantly positive. Results: 50% of 146 patients with IIM tested positive for an MSA (table 1) , compared to 3,5% of 200 disease controls (table 1). 1 SSc patient was positive for Jo-1, 1 CIDP patient was positive for PL12, 2 SSc patients were positive for TIF1-gamma, 2 patients (1 SSc and 1 SjS patient) were positive for SAE1/2, and 1 SjS patient was positive for NXP2. The prevalence of SAE1/2 and TIF1-gamma positivity was similar in the IIM and disease control group. No healthy control had a significantly positive MSA.
Antibody detected IIM Disease controls Healthy controls (n=146) (n=200) (n=40) Background: Systemic Sclerosis (SSc) is a connective tissue disorder characterized by fibrosis of skin and internal organs, vasculopathy and systemic inflammation. To date, few studies assessed pain in SSc patients,(1) namely the neuropathic component. Data is also scarce on defining possible neuropathic pain (NP) predictors in these patients. Objectives: To determine if patients with SSc have a higher prevalence of NP compared with a group of age and sex matched controls and study possible associations between NP and SSc clinical variables.
Methods:
The study evaluated patients diagnosed with SSc fulfilling the SSc classification criteria of the American College of Rheumatology (ACR), older than 18 years old and followed up at our Rheumatology Unit. Forty-eight patients with mean age of 56.98±12.73 years and mean disease duration of 9.77±6.12 years were included. Comparison group comprised 45 age and sex matched controls. Patients and controls were consecutively evaluated at our Unit and NP in 4 questions questionnaire (DN4) was used for assessing the presence of NP. In SSc patients, skin involvement was also evaluated clinically by the modified Rodnan skin thickness score (mRSS) ranging from 0 to 51. Hand mobility (HAMIS) and SSc Severity Scale (SScSS) were also calculated and relevant clinical variables of the disease were collected. Parametric and nonparametric tests were used for comparative analysis. Multivariate logistic regression was used to identify factors associated to NP. Statistical significance was defined as P<0.05. Results: In our study, prevalence of NP assessed by DN4 was significantly higher in SSc patients comparative to controls (56.2% versus 13.3%, p<0.001).
In addition to age and sex, presence of diabetes (p=0.541) was also similar in both groups. In SSc group, patients with and without NP showed some statistically significant differences (table 1) . 
